pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,822 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1772Endpoints1378Fierce Biotech697BioSpace689BioPharma Dive522raps231onclive165fda recalls
therapy area
allOncology12280Rare Disease3178Immunology2859Cardiology2719Hematology2154Pulmonology2135Vaccines
  • Ambient scribing startups draw attention as Abridge secures $300 million funding
    Last summer, a wave of ambient scribing startups captured the health-tech spotlight. These companies employ artificial-intelligence systems that listen to doctor-patient conversations and automati…
    Endpoints · 3mo agoDealNeutral↗ source
  • Akido expands AI-driven patient intake and diagnostic tools to 100 clinics
    Akido, a health‑technology startup, announced it will deploy its artificial‑intelligence platform for patient intake and diagnostic assistance in 100 clinics. The AI system captures patient inform…
    Endpoints · 3mo agoDealPositive↗ source
← prev
page 38 of 73
next →
111
fda medwatch109
globenewswire health73
fda press59
1787
Psychiatry & CNS1200
Ophthalmology1036
Endocrinology & Metabolism775
Pain768
Nephrology758
  • Bayer plans German launch of new stroke drug despite healthcare spending cuts
    Bayer announced it will move forward with the launch of its new stroke medication in Germany. The decision comes even though Germany has introduced a new healthcare spending bill that reduces reim…
    Endpoints · 3mo agoNeutral↗ source
  • Merck's anti-TL1A antibody shows benefit in hidradenitis suppurativa but misses endpoint in rare lung disease trial
    Merck reported mixed results from its anti‑TL1A antibody, a product of its $10.8 billion acquisition of Prometheus Biosciences. In a mid‑stage study for hidradenitis suppurativa, the antibody met…
    Endpoints · 3mo agoNeutral↗ source
  • AstraZeneca and Bristol Myers Squibb rumored to be in talks for a major merger
    Over the weekend, reports emerged that AstraZeneca and Bristol Myers Squibb were reportedly discussing a possible merger. Industry observers note that such a combination would create one of the la…
    Endpoints · 3mo agoDealNeutral↗ source
  • Merck to test experimental sac-TMT antibody-drug conjugate with Keytruda in lung cancer trial
    Merck announced it will start a clinical trial testing its experimental antibody-drug conjugate sac-TMT together with the immunotherapy Keytruda in patients with lung cancer. The study will assess…
    Endpoints · 3mo agoNeutral↗ source
  • Pfizer adds $2.5 billion to cost-cutting plan, pushing total savings past $10 billion
    Pfizer announced on Tuesday an additional $2.5 billion of cost reductions across the company, extending its multi-year austerity program. The new cuts bring the cumulative savings effort to more t…
    Endpoints · 3mo agoNegative↗ source
  • US-China biotech rivalry sparks calls for deeper discussion, says editor
    The editor notes that the ongoing debate over the competitive relationship between U.S. and Chinese biotechnology sectors has been unfolding over recent months. While many knowledgeable voices are…
    Endpoints · 3mo agoNegative↗ source
  • Early Alert: Intraosseous Needle Set Issue from Becton Dickinson
    BD is recalling certain BD Intraosseous Vascular Access System Needle Sets due to difficulty removing the obturator (stylet) following placement.
    fda medwatch · 3mo agoRegulatoryNeutral↗ source
  • Amgen drops early-stage obesity drug candidate AMG-513
    Amgen announced it is discontinuing its early-stage obesity candidate AMG-513. The program was in Phase 1, but the company provided no details about the study or the reasons for the halt. A spokes…
    Endpoints · 3mo agoNegative↗ source
  • Liebel-Flarsheim recalls OPTIRAY imaging contrast agent after detecting plastic, metal and glass particles
    Liebel-Flarsheim Company announced a recall of one lot of its OPTIRAY Imaging Bulk Package, a 350/500 mL vial of ioversol injection used for intra‑arterial and intravenous imaging. The recall was…
    fda medwatch · 3mo agoCRLNegative↗ source
  • Novo vs. Lilly: Q2's cardiometabolic grudge match
    For years, Novo Nordisk and Eli Lilly have dominated the conversation surrounding obesity medicines as the duopoly competes to lead the largest pharmaceutical category in history. While dozens of c…
    Endpoints · 3mo agoNeutral↗ source
  • Blank Slate Creamery recalls vegan coconut fudge sandwiches over undeclared egg allergen
    Blank Slate Creamery of Ann Arbor, Michigan announced a recall of its 4.5‑ounce vegan non‑dairy frozen dessert coconut fudge sandwiches because the product may contain egg, an undeclared allergen.…
    fda recalls · 3mo agoCRLNegative↗ source
  • FDA expands Pluvicto label, allowing most metastatic prostate cancer patients to receive the therapy
    The U.S. Food and Drug Administration has approved an expanded label for Novartis’ radiopharmaceutical Pluvicto, permitting its use together with hormone therapy in metastatic prostate cancer. The…
    Endpoints · 3mo agoApprovalPositive↗ source
  • Curium to acquire Lantheus in $8 billion deal, offering $102.5 per share with upside potential
    Curium announced it will purchase radiopharmaceutical company Lantheus in a transaction valued at about $8 billion. The agreement sets the purchase price at $102.5 for each Lantheus share, and inc…
    Endpoints · 3mo agoDealNeutral↗ source
  • Analysts Question Potential AstraZeneca-Bristol Myers Megamerger
    Analysts are scrutinizing a recent report that suggests AstraZeneca could merge with Bristol Myers Squibb. The proposed megamerger has sparked a series of questions about strategic fit and executio…
    Endpoints · 3mo agoDealNeutral↗ source
  • Supernus and Indivior announce all-stock merger to create CNS-focused drugmaker
    Supernus Pharmaceuticals and Indivior Pharmaceuticals have signed an all‑stock merger agreement to combine their businesses. The new company will be dedicated to developing treatments for central…
    Endpoints · 3mo agoDealPositive↗ source
  • Dash Bio secures $30 million Series A funding led by Oak HC/FT
    Dash Bio announced it has closed a $30 million Series A financing round, with Oak HC/FT serving as the lead investor. The capital will be used to expand the company’s platform that offers cloud‑sty…
    Endpoints · 3mo agoDealPositive↗ source
  • Amgen reports hackers stole patient and company data in cloud breach
    Amgen disclosed on Friday that hackers have accessed and taken both company and patient information in a cyber-attack. The company said the intrusion was detected as "unauthorized activity" affect…
    Endpoints · 3mo agoNegative↗ source
  • BD recalls specific lots of intraosseous needle sets over obturator removal issues
    BD announced a voluntary recall of certain lots of its intraosseous vascular access system needle sets after users reported difficulty removing the obturator after placement. The issue is linked t…
    fda medwatch · 3mo agoCRLNegative↗ source
  • China's biotech surge highlights work-life tension for industry leaders
    China's biotechnology sector is accelerating, prompting discussions about the demanding work culture among its leaders. Shefali Agarwal, the US‑based chief executive of Sironax, said she works lon…
    Endpoints · 3mo agoNeutral↗ source
  • Medical Action Industries issues correction for convenience kits with recalled Namic manifolds
    Medical Action Industries has issued a correction notice for certain convenience kits that contain Namic manifolds previously recalled by Medline. The company advises customers to immediately chec…
    fda medwatch · 3mo agoCRLNegative↗ source
  • BioNTech appoints Sobi's Guido Oelkers as new CEO, to start by Feb 1 2027
    BioNTech announced that Guido Oelkers, currently a leader at Swedish biotech company Sobi, will become its next chief executive officer. Oelkers is expected to take over the role no later than Feb…
    Endpoints · 3mo agoNeutral↗ source
  • Medline orders correction of convenience kits containing lidocaine and bupivacaine in dextrose injection
    Medline has issued a correction for certain convenience kits that include lidocaine hydrochloride and bupivacaine hydrochloride mixed with dextrose injection. The FDA has classified this recall as…
    fda medwatch · 3mo agoCRLNegative↗ source
  • American Regent recalls two lots of Adequan canine injection and two lots of Adequan i.m. for horses due to glass fibers
    American Regent Animal Health announced a nationwide recall of specific lots of its Adequan products for dogs and horses. The recall includes two lots of the 100 mg/mL 5 mL multi‑dose canine injec…
    fda medwatch · 3mo agoCRLNegative↗ source